Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diego Teyssonneau

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Opinion on Biological Therapy|July 11, 2017
Olaratumab for soft tissue sarcomaDiego Teyssonneau, Antoine Italiano
Current Opinion in Urology|September 19, 2025
Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancerRomain Iaxx, Diego Teyssonneau, Catherine Fallaha, et al.
BMC Cancer|May 13, 2017
Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected responseDiego Teyssonneau, Amaury Daste, Vincent Dousset, et al.
Med (New York, N.Y.)|January 11, 2025
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedsideFlorent Peyraud, Jean-Philippe Guegan, Lucile Vanhersecke, et al.
Critical Reviews in Oncology/Hematology|April 14, 2018
Treatment of spinal metastases in renal cell carcinoma: A critical reviewDiego Teyssonneau, Marine Gross-Goupil, Charlotte Domblides, et al.
Journal of Hematology & Oncology|March 30, 2021
Prostate cancer and PARP inhibitors: progress and challengesDiego Teyssonneau, Henri Margot, Mathilde Cabart, et al.
Critical Reviews in Oncology/Hematology|November 23, 2024
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trialsCamille Baudelin, Paul Sargos, Derek Dinart, et al.
European Urology Oncology|May 16, 2024
Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial ProtocolPaul Sargos, Carine Bellera, Rita Bentahila, et al.
Cancer Medicine|August 12, 2021
Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancerCedric Pobel, Edouard Auclin, Diego Teyssonneau, et al.
Clinical Genitourinary Cancer|December 5, 2025
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA StudyThibaut Reverdy, Floriane Izarn, Benoit Allignet, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Opinion on Biological Therapy|July 11, 2017
Olaratumab for soft tissue sarcomaDiego Teyssonneau, Antoine Italiano
Current Opinion in Urology|September 19, 2025
Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancerRomain Iaxx, Diego Teyssonneau, Catherine Fallaha, et al.
BMC Cancer|May 13, 2017
Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected responseDiego Teyssonneau, Amaury Daste, Vincent Dousset, et al.
Med (New York, N.Y.)|January 11, 2025
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedsideFlorent Peyraud, Jean-Philippe Guegan, Lucile Vanhersecke, et al.
Critical Reviews in Oncology/Hematology|April 14, 2018
Treatment of spinal metastases in renal cell carcinoma: A critical reviewDiego Teyssonneau, Marine Gross-Goupil, Charlotte Domblides, et al.
Journal of Hematology & Oncology|March 30, 2021
Prostate cancer and PARP inhibitors: progress and challengesDiego Teyssonneau, Henri Margot, Mathilde Cabart, et al.
Critical Reviews in Oncology/Hematology|November 23, 2024
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trialsCamille Baudelin, Paul Sargos, Derek Dinart, et al.
European Urology Oncology|May 16, 2024
Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial ProtocolPaul Sargos, Carine Bellera, Rita Bentahila, et al.
Cancer Medicine|August 12, 2021
Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancerCedric Pobel, Edouard Auclin, Diego Teyssonneau, et al.
Clinical Genitourinary Cancer|December 5, 2025
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA StudyThibaut Reverdy, Floriane Izarn, Benoit Allignet, et al.
Pageof 2